ATNM News and Press, Actinium Pharmaceuticals Inc. From 10/31/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com Welcome back and get ready for another week of trading with the biggest pre-market stock movers for Monday! We’ve got clinical trial data, reverse stock splits, as well as...

Actinium Pharmaceuticals ( NYSE: ATNM ), a biotech focused on targeted radiotherapies, jumped ~23% pre-market Monday after announcing that its lead product candidate Iomab-B met the primary endpoint in a pivotal Phase 3 trial involving patients with acute myeloid leukemia ...

Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia PR Newswire -  Iomab-B met the primary endpoint of durable complete remission of 6-months following initia...

Summary Riding two powerful franchises (Iomab and Actimab), Actinium Pharmaceuticals is brewing a deep pipeline of therapeutics for multiple indications. There is also AWE Technology that is developed in collaboration with other biotech innovators. The best time to consider pi...

Actinium Expands Clinical Leadership Team to Support Key Development Programs for Iomab-B and Actimab-A PR Newswire Key hires with proven expertise and track records in Bone Marrow Transplant, Acute Myeloid Leukemia, Radiation Sciences and Clinical Operations position ...

Actinium Pharmaceuticals to Participate in the 2022 Bio-Europe Conference PR Newswire NEW YORK , Oct. 26, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radio...

Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B PR Newswire Jenny Hsieh joins Actinium as Chief Strategy Officer from Gilead Sciences, following its acquisition of Immunomedics Sunitha Lakshminarayanan , Senior Vice ...

Summary Actinium Pharmaceuticals, Inc.'s results from the phase 3 SIERRA trial, using Iomab-B as a preconditioning agent in patients over the age of 55 with active relapsed/refractory AML are expected Q4 of 2022. Prior study shows that 100% of patients who received Iomab-B were ab...

Actinium to Present at the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference Actinium to Present at the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference PR Newswire NEW YORK , Sept. 26, 2022 /PRNewswire/ -- Actinium Phar...

Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones PR Newswire On track to report topline data from the Pivotal Phase 3 SIERRA trial for Iomab-B in Q4 2022 Overall survival data from...